Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium voltage-gated channel subfamily H member 4 (KCNH4) is a pore-forming (alpha) subunit of voltage-gated delayed rectifier potassium channels, part of the larger KCNH (eag/ELK/ERG) family[2][3][4][7]. KCNH4 channels are tetrameric, each subunit containing six transmembrane segments and specialized voltage-sensing and pore domains[2][3][5]. These channels activate at more negative voltages and exhibit fast, prepulse-independent kinetics, contributing to the repolarization phase of the membrane potential and modulating action potential firing in neurons[2][4]. KCNH4 is expressed predominantly in the brain and is involved in setting the electrical excitability of neurons and shaping action potential characteristics[7]. While other KCNH family members like KCNH2 (hERG) are established drug targets in cardiac and oncological indications, specific drugs or disease associations for KCNH4 remain unreported. Despite the lack of direct small-molecule ligands or clinical biomarkers, KCNH4’s structural and functional properties implicate it as an important modulator within neural circuits[2][3][7]. Additional context: - KCNH4 channels do not bind cyclic nucleotides directly, instead containing a “cyclic nucleotide-binding homology domain” regulated by an intrinsic ligand within their C-terminal region[3]. - They are categorized within the *Kv12* subfamily (Kv12.3), which are slowly activating voltage-gated potassium channels[5]. - Dysfunction in related KCNH channels is implicated in long QT syndrome and cancer, but direct disease links for KCNH4 are not described in the literature[3][7]. Note: - No therapeutically approved drugs, clinical biomarkers, or specific patient safety concerns have been reported for KCNH4 as of the current knowledge base[4][7]. - Disease and functional roles are inferred from family characteristics and expression profile; caution should be used when extrapolating to clinical significance for KCNH4 specifically.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium voltage-gated channel subfamily H member 4 (KCNH4).